Close on the heels of its investigation of GlaxoSmithKline for “economic crimes,” China’s Federation of Industry and Commerce has contacted German drug giant Bayer in relation to an antitrust probe. A spokesman for Bayer said, “We assume that this contact is related to a wider investigation into the pharmaceutical industry in China.” Sales in China constitute 19.5% of the company’s worldwide total.

Read the entire article, “After GSK, Bayer also targeted in Chinese pharmaceutical probe”